The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS: We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures. RESULTS: As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. CONCLUSIONS: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Wells G, 2008, Cochrane Database Syst Rev, 1, CD004523
- Martin TJ, 2004, J Musculoskelet Neuronal Interact, 4, 243
Cited by
Sorted by citations
Items 801–900 of 1,006
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 42
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis
Josse, R. G., Khan, A. A., Ngui, D., & Marla Shapiro, C. M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.763779 · Cited by 44
Denosumab for bone diseases: translating bone biology into targeted therapy
Tsourdi, E. A., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0454 · Cited by 41
Hypercalcemia after discontinuation of long-term denosumab treatment
Sølling, A. S., Harsløf, T., Kaal, A., Rejnmark, L., & Langdahl, B. L. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3535-5 · Cited by 41
Glendenning, P., Chubb, S. A. P., & Vasikaran, S. D. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.009 · Cited by 44
Zhang, L., Zhou, J.-J., & Luo, C. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1722-9 · Cited by 41
Aro, H. T., Nazari‐Farsani, S., Vuopio, M., Löyttyniemi, E., & Mattila, K. T. (2019) · JBMR Plus · doi:10.1002/jbm4.10217 · Cited by 42
A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab
Chotiyarnwong, P., McCloskey, E. V., Eastell, R., McClung, M. R., Gielen, E., Gostage, J., McDermott, M., Chines, A. A., Huang, S., & Cummings, S. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3972 · Cited by 41
Self-citationDenosumab for management of severe hypercalcemia in primary hyperparathyroidism
Константиновна, Е. А., Krupinova, J. A., Dobreva, E. A., Gorbacheva, A. M., Евгеньевна, Б. Е., Samsonova, M. D., Elfimova, A. R., & Mokrysheva, N. (2020) · Endocrine Connections · doi:10.1530/ec-20-0380 · Cited by 41
Hiramatsu, R., Ubara, Y., Sawa, N., & Sakai, A. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa359 · Cited by 41
Interventions for preventing bone disease in kidney transplant recipients
Palmer, S. C., Chung, E. Y. M., McGregor, D., Bachmann, F., & Strippoli, G. F. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005015.pub4 · Cited by 41
Hautmann, A. H., Elad, S., Lawitschka, Á., Greinix, H., Bertz, H., Halter, J. P., Faraci, M., Hofbauer, L. C., Lee, S. J., Wolff, D., et al. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01264.x · Cited by 41
Ip, T., Cheung, S.-K. W., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 41
Calcitonin: A useful old friend.
Srinivasan, A., Wong, F. Y. K., & Karponis, D. (2020) · PubMed Central · Cited by 39
Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
Tay, W. L., & Tay, D. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1369 · Cited by 40
Proximal Junctional Failure in Adult Spinal Deformity Surgery: An In-depth Review
Yagi, M., Yamanouchi, K., Fujita, N., Funao, H., & Ebata, S. (2023) · Neurospine · doi:10.14245/ns.2346566.283 · Cited by 40
Rauner, M., Thiele, S., Sinningen, K., Winzer, M., Salbach‐Hirsch, J., Gloe, I., Peschke, K., Haegeman, G., Tuckermann, J. P., & Hofbauer, L. C. (2013) · Endocrinology · doi:10.1210/en.2012-2221 · Cited by 40
The effect of treatments for osteoporosis on mortality
Grey, A. B., & Bolland, M. J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2176-6 · Cited by 38
Goessl, C. D., Katz, L., Dougall, W. C., Kostenuik, P. J., Zoog, H. B., Braun, A., Dansey, R., & Wagman, R. B. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06674.x · Cited by 40
Self-citationBone fractures after menopause
The ESHRE Capri Workshop Group (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq008 · Cited by 47
Yazdi, P. M., & Schiødt, M. (2015) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2014.12.024 · Cited by 40
Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review
Diédhiou, D., Cuny, T., Sarr, A., Diop, S. N., Klein, M., & Weryha, G. (2015) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.10.009 · Cited by 41
Surgery alters parameters of vitamin D status and other laboratory results
Binkley, N., Coursin, D. B., Krueger, D. C., Iglar, P., Heiner, J. P., Illgen, R. L., Squire, M., Lappe, J. M., Watson, P. A., & Hogan, K. J. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3819-9 · Cited by 40
Mortality After Osteoporotic Fractures: What Proportion Is Caused by Fracture and Is Preventable?
Schousboe, J. T. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3216 · Cited by 40
The Pathophysiology of Osteoporosis after Spinal Cord Injury
Shams, R., Drasites, K. P., Zaman, V., Matzelle, D. D., Shields, D. C., Garner, D. P., Sole, C. J., Haque, A., & Banik, N. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063057 · Cited by 43
Fu, S., Wang, C., Hung, C., Lee, C., Yang, R., Huang, C., Farn, C. J., Lin, W., Chen, H., Hsiao, F., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13354 · Cited by 40
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Tonk, C. H., Shoushrah, S. H., Babczyk, P., Khaldi-Hansen, B. E., Schulze, M., Herten, M., & Tobiasch, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031393 · Cited by 44
Paternoster, L., Ohlsson, C., Sayers, A. E., Vandenput, L., Lorentzon, M., Evans, D. M., & Tobias, J. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0025 · Cited by 40
Røysland, R., Bonaca, M. P., Omland, T., Sabatine, M. S., Murphy, S. A., Scirica, B. M., Bjerre, M., Flyvbjerg, A., D, E. B. M., & Morrow, D. A. (2012) · Heart · doi:10.1136/heartjnl-2011-301260 · Cited by 40
Moshi, M. R., Nicolopoulos, K., Stringer, D., Ma, N., Jenal, M., & Vreugdenburg, T. D. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01078-z · Cited by 40
Miyamoto, T. K. (2015) · The Keio Journal of Medicine · doi:10.2302/kjm.2015-0003-re · Cited by 39
Farinola, N., & Kanjanapan, Y. (2013) · Internal Medicine Journal · doi:10.1111/imj.12283 · Cited by 39
Stopeck, A., & Brown-Glaberman, U. A. (2012) · Biologics · doi:10.2147/btt.s20677 · Cited by 39
Giant-cell tumor of bone, anti-RANKL therapy
Dufresne, A., Derbel, O., Cassier, P. A., Vaz, G., Decouvelaere, A., & Blay, J. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.149 · Cited by 39
Role of biochemical markers in the management of osteoporosis
Henriksen, K., Christiansen, C., & Karsdal, M. A. (2015) · Climacteric · doi:10.3109/13697137.2015.1101256 · Cited by 38
Self-citationEffect of Teriparatide on Bone Formation in the Human Femoral Neck
Cosman, F., Dempster, D. W., Nieves, J. W., Zhou, H., Zion, M., Roimisher, C., Houle, Y., Lindsay, R., & Bostrom, M. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3698 · Cited by 39
Diacinti, D., Vitali, C., Gussoni, G., Pisani, D., SINIGAGLIA, L., Bianchi, G., Nuti, R., Gennari, L., Pederzoli, S., Grazzini, M., et al. (2017) · Bone · doi:10.1016/j.bone.2017.05.008 · Cited by 39
Tratamiento de la osteoporosis
Nogués, X., & Martínez-Laguna, D. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.10.019 · Cited by 40
Chandran, M., Lau, T. C., Gagnon-Arpin, I., Dobrescu, A., Li, W., Leung, M. Y. M., Patil, N., & Zhao, Z. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0664-4 · Cited by 39
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz321 · Cited by 40
Kim, M. J., Kim, H. S., Lee, S.-Y., Min, K. Y., Choi, W. S., & You, J. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168888 · Cited by 43
Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?
Cannata-Andía, J. B., Carrillo‐López, N., Messina, O. D., Hamdy, N. A. T., Panizo, S., & Ferrari, S. (2021) · Nutrients · doi:10.3390/nu13113835 · Cited by 40
Miller, P. D., & Derman, R. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1208-3 · Cited by 39
Prevention and treatment of osteoporosis in women
Stevenson, J. C., & in collaboration with the medical advisory council of the British Menopause Society (2022) · Post Reproductive Health · doi:10.1177/20533691221139902 · Cited by 38
Liu, F.-C., Luk, K., & Chen, Y.-C. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06818-3 · Cited by 39
Insights into the genetics of osteoporosis from recent genome-wide association studies
Zheng, H., Spector, T. D., & Richards, J. B. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001980 · Cited by 39
Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients
Augoulea, A., Vrachnis, N., Lambrinoudaki, I. V., Dafopoulos, K. C., Iliodromiti, Z., Daniilidis, A., Varras, M. N., Alexandrou, A. P., Deligeoroglou, E., & Creatsas, G. K. (2013) · International Journal of Endocrinology · doi:10.1155/2013/182060 · Cited by 38
Schneider, D. A., Smith, S. M., Campbell, C. R., Hayami, T., Kapila, S., & Hatch, N. E. (2015) · Orthodontics and Craniofacial Research · doi:10.1111/ocr.12086 · Cited by 38
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540565 · Cited by 38
Medication-Related Osteonecrosis of the Jaw—2014 Update
Ruggiero, S. L., Dodson, T. B., Goodday, R. H. B., Aghaloo, T. L., & Mehrotra, B. (2014) · Cited by 38
A missense single nucleotide polymorphism in the ALDH2 gene, rs671, is associated with hip fracture
Takeshima, K., Nishiwaki, Y., Suda, Y., Niki, Y., Sato, Y., Kobayashi, T., Miyamoto, K., Uchida, H., Inokuchi, W., Tsuji, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00503-2 · Cited by 38
Using Osteoporosis Therapies in Combination
McClung, M. R. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0376-x · Cited by 38
Self-citationMoretti, A., Alessandro de, S. I. R. E., Curci, C., Toro, G., Gimigliano, F., & Iolascon, G. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1545636 · Cited by 38
Jähn, K., Wölfel, E. M., Jobke, B., Riedel, C., Hellmich, M., Werner, M., McDonald, M. M., & Busse, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00250 · Cited by 40
Risk factors for subsequent vertebral fracture after acute osteoporotic vertebral fractures
Inose, H., Kato, T., Ichimura, S., Nakamura, H., Hoshino, M., Togawa, D., Hirano, T., Tokuhashi, Y., Ohba, T., Haro, H., et al. (2021) · European Spine Journal · doi:10.1007/s00586-021-06741-3 · Cited by 38
Papaneophytou, C. P., Rinotas, V. E., Douni, E. K., & Kontopidis, G. A. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.04.005 · Cited by 38
Role of thymus in health and disease
Gulla, S., Reddy, M. C., Reddy, V. C., Chitta, S., Bhanoori, M., & Lomada, D. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2064461 · Cited by 39
Imaging of Site Specific Bone Turnover in Osteoporosis Using Positron Emission Tomography
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0231-2 · Cited by 37
Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis
Scott, L. J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0191-3 · Cited by 37
New horizons in osteoporosis therapies
Harsløf, T., & Langdahl, B. L. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.012 · Cited by 37
Bischoff, S., Arends, J., Dörje, F., Engeser, P., Hanke, G., Köchling, K., Leischker, A. H., Mühlebach, S., Schneider, A., Seipt, C., et al. (2013) · Aktuelle Ernährungsmedizin · doi:10.1055/s-0033-1349549 · Cited by 37
Osteoporosis in Postmenopausal Women
Sanders, S., & Geraci, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0b013e3182a0df8b · Cited by 37
Infections in De Novo Kidney Transplant Recipients Treated With the RANKL Inhibitor Denosumab
Bonani, M., Frey, D., de Rougemont, O., Mueller, N. J., Mueller, T., Graf, N., & Wuthrich, R. P. (2016) · Transplantation · doi:10.1097/tp.0000000000001547 · Cited by 37
Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab
Yarom, N., Lazarovici, T. S., Whitefield, S., Weissman, T., Wasserzug, O., & Yahalom, R. (2017) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2017.09.014 · Cited by 37
Walter, E., Dellago, H., Grillari, J., Dimai, H. P., & Hackl, M. (2017) · Bone · doi:10.1016/j.bone.2017.12.017 · Cited by 37
Voss, P. J., Steybe, D., Poxleitner, P. J., Schmelzeisen, R., Munzenmayer, C., Füllgraf, H., Stricker, A., & Semper-Hogg, W. (2018) · Odontology · doi:10.1007/s10266-018-0362-5 · Cited by 37
Harinarayan, C. V., & Akhila, H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00493 · Cited by 38
Galvano, A., Scaturro, D., Badalamenti, G., Incorvaia, L., Rizzo, S., Castellana, L., Cusenza, S., Cutaia, S., Santini, D., Guadagni, F., et al. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100252 · Cited by 37
Xu, H., Liu, T., Jia, Y., Li, J., Jiang, L., Hu, C., Wang, X., & Sheng, J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107464 · Cited by 37
Aspenberg, P., Agholme, F., Magnusson, P., & Fahlgren, A. (2010) · Bone · doi:10.1016/j.bone.2010.09.024 · Cited by 37
Safety of drugs used in the treatment of osteoporosis
McGreevy, C., & Williams, D. J. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611411012 · Cited by 37
Diagnosis and Management of Osteoporosis: A Comprehensive Review of Guidelines
Rentzeperi, E., Pegiou, S., Tsakiridis, I. G., Kalogiannidis, I. A., Kourtis, A., Mamopoulos, A. M., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001181 · Cited by 39
Smith, M. R., Fred Saad, C., Egerdie, B., SIEBER, P. R., Tammela, T. L. J., Leder, B. Z., Ke, C., & Goessl, C. D. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.492 · Cited by 36
Sclerostin and skeletal health
Sharifi, M., Ereifej, L. K., & Lewiecki, E. M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9311-6 · Cited by 37
Clinical utility of denosumab for treatment of bone loss in men and women
Adler, R. A., & Gill, R. S. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s14565 · Cited by 36
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 36
Denosumab for The Treatment of Bone Disease in Solid Tumors and Multiple Myeloma
Yee, A. J., & Raje, N. S. (2017) · Future Oncology · doi:10.2217/fon-2017-0403 · Cited by 37
Pedersen, A. B., Heide‐Jørgensen, U., Sørensen, H. T., Prieto‐Alhambra, D., & Ehrenstein, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2416 · Cited by 37
Seeto, A. H., Abrahamsen, B., Ebeling, P. R., & Rodríguez, A. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4157 · Cited by 36
Zheng, K., Bai, J., Li, N., Li, M., Sun, H., Zhang, W., Ge, G., Liang, X., Tao, H., Xue, Y., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.039 · Cited by 36
Kobayakawa, T., Miyazaki, A., Kanayama, Y., Hirano, Y., Takahashi, J. A., Suzuki, T., & Nakamura, Y. (2022) · Modern Rheumatology · doi:10.1093/mr/roac014 · Cited by 36
A Roadmap to the Brittle Bones of Cystic Fibrosis
Gore, A., Kwon, S. H., & Stenbit, A. E. (2010) · Journal of Osteoporosis · doi:10.4061/2011/926045 · Cited by 38
Leistner, D. M., Seeger, F. H., Fischer, A., Roexe, T., Klotsche, J., Iekushi, K., Seeger, T., Aßmus, B., Honold, J., Karakas, M., et al. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.966093 · Cited by 37
Tang, W., Ding, Z., Gao, H., Yan, Q., Liu, J., Han, Y., Hou, X., Liu, Z., Chen, L., Yang, D., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.001 · Cited by 35
Surface patches induce nonspecific binding and phase separation of antibodies
Ausserwӧger, H., Krainer, G., Welsh, T. J., Thorsteinson, N., de Csilléry, E., Šneideris, T., Schneider, M. M., Egebjerg, T., Invernizzi, G., Herling, T. W., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210332120 · Cited by 35
Cheng, S., Chu, W., Chou, W.-H., Chu, W., & Kang, Y. (2024) · Drug Safety · doi:10.1007/s40264-024-01475-9 · Cited by 35
Qu, B., Xia, X., Yan, M., Gong, K., Deng, S.-L., Huang, G., Ma, Z., & Pan, X. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.07.023 · Cited by 35
Potential role of odanacatib in the treatment of osteoporosis
Ng, K. W. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s26729 · Cited by 35
Edwards, W. B., Schnitzer, T. J., & Troy, K. L. (2013) · Bone · doi:10.1016/j.bone.2013.12.012 · Cited by 37
Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
Borgström, F., Ström, O., Kleman, M., McCloskey, E. V., Johansson, H., Odén, A., & Kanis, J. A. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1291-5 · Cited by 35
Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial
Wustrack, R. L., Seeman, E., Bucci-Rechtweg, C. M., Burch, S., Palermo, L., & Black, D. M. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1664-4 · Cited by 35
Kumagai, Y., Hasunuma, T., & Padhi, D. (2011) · Bone · doi:10.1016/j.bone.2011.08.007 · Cited by 34
Szekanecz, Z., Szántó, S., Szabó, Z., Váncsa, A., Szamosi, S., Bodnár, N., & Szűcs, G. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.011 · Cited by 34
Novel Therapies for Postmenopausal Osteoporosis
Bandeira, L., & Bilezikian, J. P. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.11.001 · Cited by 35
Keshishian, A. V., Boytsov, N. N., Burge, R. T., Krohn, K., Lombard, L., Zhang, X., Xie, L., & Baser, O. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4072-6 · Cited by 35
Grossmann, M., Ramchand, S. K., Milat, F., Vincent, A. J., Lim, E., Kotowicz, M. A., Hicks, J., & Teede, H. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13735 · Cited by 35
RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
Tanaka, S. (2019) · F1000Research · doi:10.12688/f1000research.17296.1 · Cited by 35
Jiang, M., Peng, L., Yang, K., Wang, T., Yan, X., Jiang, T., Xu, J., Jin, Q., Zhou, H., Qian, N., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02027 · Cited by 35
Huang, Y.-Y., Wang, Z.-H., Deng, L.-H., Wang, H., & Zheng, Q. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6080597 · Cited by 38
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
Ström, O., Jönsson, B., & Kanis, J. A. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2115-6 · Cited by 35
Metadata
- Authors
- Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., & Christiansen, C.
- Affiliations
- University of California, San Francisco (US)
- Columbia University Irving Medical Center (US)
- University of Sheffield (GB)
- University of Auckland (NZ)
- Inserm (FR)
- Amgen (United States) (US)
- University of Verona (IT)
- Center for Clinical & Basic Research (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-20
- Volume
- 361
- Issue
- 8
- Pages
- 756-765
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160005424
- Cited by
- 3,489
- References
- 39
- Citations by year
- 2026: 187 · 2025: 220 · 2024: 203 · 2023: 164 · 2022: 226 · 2021: 210 · 2020: 223 · 2019: 200 · 2018: 208 · 2017: 195 · 2016: 180 · 2015: 238 · 2014: 168 · 2013: 222 · 2012: 197
- FWCI
- 223.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- denosumab, osteoporosis, postmenopausal women, fracture prevention, RANKL inhibition, vertebral fractures, hip fracture, non-vertebral fractures, bone mineral density, monoclonal antibodies, osteoclasts, bone resorption, adverse events, osteonecrosis of the jaw, hypocalcemia, cancer risk, cardiovascular risk
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Female, Hip Fractures, Humans, Middle Aged, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
